The activists have called out the FDA for giving Gilead Sciences, who have been repeatedly accused of price gouging, a monopoly on a possible COVID-19 treatment.
“If the plan does not explicitly address the unique needs of these populations, it will fail,” says Raniyah Copeland, president of the Black AIDS Institute.